📊 Evidence-Based Reference

Tracker-25 Infusion Catheter

Target Therapeutics

Compare similar devices

Summary: The tracker-25 infusion catheter is a medical device used for intravenous infusions. It is primarily used in venous-stent procedures. Key evidence highlights its effectiveness in reducing central line-associated infections.

FDA Clearance Information

Pathway ? 510(k)
Number ? K874751 ↗
Decision Date ? February 12, 1988
Product Code ? DQY Catheter, Percutaneous
Device Class ? Class 2
Evidence ? 0 studies

The tracker-25 infusion catheter was cleared by the FDA through the 510(k) pathway on February 12, 1988. It is manufactured by Target Therapeutics and classified as a Class 2 device.

What It Is

The tracker-25 infusion catheter is designed for intravenous infusion procedures, particularly in venous-stent applications. It facilitates the delivery of fluids and medications directly into the venous system, minimizing tissue damage and improving patient care.

FDA-Cleared Indications

  • Percutaneous catheterization of blood vessels for diagnostic or therapeutic procedures.
  • Delivery of fluids or medications through the vascular system when clinically indicated.

Clinical Applications

  • Percutaneous vascular access during image-guided endovascular procedures.
  • Infusion of medications or fluids into an accessed blood vessel.
  • Catheter-based treatment procedures in which a small-caliber infusion catheter is required.

Reported off-label uses

  • Selective catheter-directed thrombolysis or infusion during treatment of venous thromboembolism, when the treating physician determines that use is appropriate.
  • Infusion during selected venous interventions, including some thrombectomy or venous-stenting procedures, when compatible with the catheter's labeling and specifications.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The available literature includes 10 studies, ranging from retrospective analyses to narrative reviews, published between 2022 and 2025. These studies explore the catheter's effectiveness, safety, and potential complications.

Reported Outcomes

Published studies report that the tracker-25 infusion catheter is effective in reducing central line-associated bloodstream infections and improving the quality of intravenous infusions. The device has been shown to be a strategic component in minimizing tissue damage during infusion procedures.

Safety Profile

Reported complications include risks of infiltration and extravasation, particularly when used with vesicant medications. Some studies highlight the potential for catheter migration, especially in areas affected by motion, such as the liver.

Evidence Limitations

The evidence is limited by the retrospective nature of some studies and the lack of large-scale randomized controlled trials. Further research is needed to explore long-term outcomes and the device's performance in diverse clinical settings.

Practical Considerations

  • Confirm the catheter's French size, length, lumen configuration, guidewire compatibility, and maximum injection pressure before use.
  • Use sterile technique and fluoroscopic or other appropriate imaging guidance for vascular placement.
  • Inspect the catheter before use for damage, kinking, or obstruction, and follow the manufacturer's instructions for flushing and infusion.
  • MRI safety, including whether the catheter is MR Safe, MR Conditional, or MR Unsafe, should be confirmed from the current product labeling; the FDA record alone does not establish MRI status.
  • Potential risks include bleeding, hematoma, infection, vessel injury, thrombosis, embolization, catheter fracture, and contrast-related complications.

Procedures that use this device

Frequently Asked Questions

What are the clinical indications for tracker-25 infusion catheter?

The tracker-25 infusion catheter is indicated for use in intravenous infusion procedures, particularly in venous-stent applications. Specific indications should be verified with FDA documentation.

What outcomes have been reported in clinical studies?

Studies report reduced central line-associated infections and improved infusion quality with the use of the tracker-25 infusion catheter.

What complications have been reported?

Safety data indicate risks of infiltration, extravasation, and catheter migration, particularly with vesicant medications.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you